Navigation Links
A search for protection against chemotherapy cardiotoxicity
Date:12/20/2007

Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. The research article describing this work entitled Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts will be featured in the January 2008 issue of Experimental Biology and Medicine. Although rare, cardiotoxicity is a serious complication of cancer treatment. Indeed, the use of chemotherapeutic agents such as anthracycline or trastuzumab in oncology is limited by their cardiac toxicity. Therefore, it is of interest to identify new protective agents preventing these adverse effects.

The increasing use of doxorubicin and trastuzumab in adjuvant breast cancer therapy and the growing population of long-term pediatric cancer survivors mean that, more than ever, cardiotoxicity will continue to remain an important issue for oncology. Cardiomyopathy induced by chronic chemotherapy may result, at least in part, from acute cardiotoxic effects accompanying each drug exposure. said Professor Mireille Mousseau, head of the Department of Oncology.

The research team, led by Christophe Ribuot, a professor of pharmacology, explored the beneficial cardioprotective effect afforded by recombinant human erythropoietin (rhEPO) against various stresses, through experimental and clinical investigations.

This study is an excellent illustration of a fruitful collaboration between researchers in experimental pharmacology, Christophe Ribuot and Marie Joyeux-Faure, and the oncologist M. Mousseau. Here, we observed for the first time that only a unique rhEPO administration prevents cardiac damage induced by an acute doxorubicin or trastuzumab exposure, using the isolated rat heart model. said the articles first author Amandine Ramond. RhEPO administration could, therefore, be used during chemotherapy administration to reduce acute cardiotoxic effects accompanying each drug exposure and, potentially, to prevent long-term development of cardiomyopathy. Further clinical investigations are now needed to explore the potential benefit of rhEPO in oncology.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said Amandine Ramond and her colleagues have provided an insightful study demonstrating that rhEPO can reduce the cardiotoxic effects of chemotherapeutic agents, doxorubicin and trastzumab, in a rat heart model. If rhEPO has similar effects on humans then this study will be of substantial benefit to cancer patients worldwide.


'/>"/>

Contact: Dr. Marie Faure
marie.faure@ujf-grenoble.fr
01-133-476-637-475
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Newly created cancer stem cells could aid breast cancer research
3. Dominant cholesterol-metabolism ideas challenged by new research
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. U of MN researchers discover noninvasive diagnostic tool for brain diseases
10. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
11. Story ideas from the Journal of Lipid Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):
(Date:5/20/2016)... ... ... Kablooe Design, a leading provider of product design and development services to medical ... “We have worked hard to build long-term relationships,” says President and CEO, Tom KraMer. ... serving their product design and development needs through the years.” , Kablooe has earned ...
(Date:5/20/2016)... ... May 20, 2016 , ... The recent recall by ... reported by Food Safety News on May 12, 2016(1), demonstrates the need for faster ... CEO of Baltimore-based biotech firm, PathSensors, Inc. , PathSensor’s latest solution ...
(Date:5/19/2016)... RIDGE, British Columbia , May 19, 2016 ... AdvanTec Global Innovations Inc. (AGI), based out of ... recently added Greenlane Biogas Ltd. to its existing ... 2-year contract manufacturing agreement. AFS along with its ... Technologies (ABT) is a vertically integrated industrial group ...
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS ... welcomed Abu Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui ... translational biomarker discovery studies for preclinical and clinical safety programs. “We’ve seen significant ...
Breaking Biology Technology: